Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Cash from Financing Activities (2016 - 2026)

Akebia Therapeutics has reported Cash from Financing Activities over the past 10 years, most recently at -$4.8 million for Q4 2025.

  • Quarterly Cash from Financing Activities fell 121.72% to -$4.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $72.9 million through Dec 2025, up 46.84% year-over-year, with the annual reading at $72.9 million for FY2025, 46.84% up from the prior year.
  • Cash from Financing Activities was -$4.8 million for Q4 2025 at Akebia Therapeutics, down from $1.1 million in the prior quarter.
  • Over five years, Cash from Financing Activities peaked at $74.9 million in Q1 2025 and troughed at -$32.9 million in Q3 2022.
  • The 5-year median for Cash from Financing Activities is $1.5 million (2024), against an average of $12.3 million.
  • Year-over-year, Cash from Financing Activities plummeted 128900.0% in 2023 and then soared 2346.0% in 2024.
  • A 5-year view of Cash from Financing Activities shows it stood at $5.4 million in 2021, then plummeted by 100.02% to -$1000.0 in 2022, then plummeted by 128900.0% to -$1.3 million in 2023, then surged by 1830.62% to $22.3 million in 2024, then tumbled by 121.72% to -$4.8 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Cash from Financing Activities are -$4.8 million (Q4 2025), $1.1 million (Q3 2025), and $1.7 million (Q2 2025).